Swiss biotech EraCal Therapeutics' founding team, Dr. Josua Jordi and Dr. Simon Breitler, received the BioBusiness-MIT Alumni Life Science Angels award for their business idea, as part of the "BioBusiness" continuing education program at the Università della Svizzera italiana.

Thanks to a new collaboration with the MIT Alumni Life Science Angels, the team of founders is now invited to Boston to present their business idea with the prospect of further financing.

The young company EraCal Therapeutics, whose scientific basis was laid at the University of Zurich and Harvard University, is developing a new specific appetite suppressant that is more effective than previous drugs and also causes fewer side effects. The therapeutic agent is intended to help reduce weight and thus also reduce the risks of other diseases. EraCal Therapeutics won Venture Kick in January 2019 and received its first investment from the Life Sciences Fund.

Josua Jordi, one of EraCal's founders, summarizes: "My expectations were sky-high. Despite an unbelievable number of competing initiatives, many founders called the "BioBusiness" program the best further education in the field of BioEntrepreneurship in Switzerland. I was not disappointed, it was really a fantastic learning experience".

Dr. Heidrun Flaadt Cervini, Director of CASE BioMed and initiator of the "BioBusiness" program, adds: "In almost 10 years we have trained about 350 young entrepreneurs with the most promising European business ideas in the life science sector. Our university is considered a pioneer in academic life science entrepreneurship education. We are very pleased that with the BioBusiness-MIT Alumni Life Science Angels Award we can now offer our BioBusiness participants direct access to an exclusive circle of investors and experts at one of the world's best universities and in a dynamic international start-up environment.